Celcuity Inc. (CELC) FDA Sets June 25, 2027 Review Goal for sNDA
Celcuity Inc. (CELC) announced the FDA accepted its supplemental New Drug Application (sNDA) for REVTORPYK, aiming to treat a specific type of breast cancer. The FDA set a goal date of June 25, 2027, for review. This follows the drug's expected approval in July 2026 for patients without a detected PIK3CA mutation.
How this was made
The 30-second read
Why it matters
The new sNDA extends the indication to HR+/HER2- PIK3CA‑mutant metastatic breast cancer, adding a future growth catalyst.
Market read
Regulatory update introduces a new milestone date, keeping the stock under watch for future approval outcomes.
What to watch
Potential for accelerated review or breakthrough designation could shorten timeline.
Background
Celcuity's REVTORPYK previously received FDA approval for a broader patient population in July 2026.
Ticker impact
FDA accepted Celcuity's sNDA for REVTORPYK and set a PDUFA goal date of June 25, 2027.
potential modest downside as investors price in the extended review timeline
Regulatory acceptance without approval extends the timeline; biotech stocks often face pressure during long review periods.
Market effects
May affect other breast‑cancer biotech peers awaiting FDA decisions.
Limited to US biotech sector.
Low global impact beyond the niche oncology market.
Counterpoint
If the review proceeds smoothly, the stock could rally on positive surprise ahead of the PDUFA date.
Key entities
- CompanyCelcuity Inc.
US‑listed biotech developing REVTORPYK.
- RegulatorFDA
U.S. Food and Drug Administration reviewing the sNDA.
